At A Glance

Name: Mark Baker

Position: CEO, Australian Proteome Analysis Facility, Sydney, since 2003

Professor of Proteomics, Macquarie University, Sydney, since 2003

Background: Director of Biomarker Discovery, LumiCyte, 2001-2003

Foundation Director, Gynaecological Cancer Research Center, Melbourne, 1998-2001

Associate Professor, University of Melbourne, 1998-2001

Associate Professor, University of Wollongong, Australia, 1992-1998

Research Fellow, Australian National University, 1988-1992

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.